PT  - JOURNAL ARTICLE
AU  - Khor, Seik-Soon
AU  - Omae, Yosuke
AU  - Takeuchi, Junko S.
AU  - Fukunaga, Ami
AU  - Yamamoto, Shohei
AU  - Tanaka, Akihito
AU  - Matsuda, Kouki
AU  - Kimura, Moto
AU  - Maeda, Kenji
AU  - Ueda, Gohzoh
AU  - Mizoue, Tetsuya
AU  - Ujiie, Mugen
AU  - Mitsuya, Hiroaki
AU  - Ohmagari, Norio
AU  - Sugiura, Wataru
AU  - Tokunaga, Katsushi
TI  - Association study of HLA with the kinetics of SARS-CoV-2 spike specific IgG antibody responses to BNT162b2 mRNA vaccine
AID  - 10.1101/2022.02.01.22270285
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.01.22270285
4099  - http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270285.short
4100  - http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270285.full
AB  - BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4+ & CD8+ T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (P = 0.017; Odd ratio (OR) 2.80, 95%Confidence interval (CI) 1.05–7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2 while DQB1*06:01:01:01 (P = 0.028, OR 0.27, 95%CI 0.05–0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (P = 0.058; OR 0.42, 95%CI 0.15–1.16), B*52:01:01 (P = 0.031; OR 0.38, 95%CI 0.14–1.03), DQA1*03:02:01 (P = 0.028; OR 0.39, 95%CI 0.15–1.00) and DPB1*02:01:02 (P = 0.024; OR 0.45, 95%CI 0.21–0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination.Competing Interest StatementGohzoh Ueda is one of employees of Abbott Japan, which provided the antibody assay reagents and funding for the present study. The Role of the funder/sponsor is described above.Funding StatementThis research is supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP20kk0205012 and JP20fk0108104, the NCGM Intramural Research Fund 20A2002D, 21A006, 19K059 and 2020-B-09) and Abbott Japan (grant number 20C050).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics Committee of the NCGM, Japan (approval number: NCGM-A-004175-00). Written informed consent was obtained from all participants prior to enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript